Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24124141 | 1.00 | LMNA (0.30) | LMNAHPGD | |
| SCHEMBL26485065 | 0.82 | GRM2 (0.31) | — | |
| SCHEMBL26485069 | 0.82 | GRM2 (0.31) | — | |
| SCHEMBL23077133 | 0.80 | BCHE (0.35) | — | |
| SCHEMBL23077179 | 0.79 | LMNA (0.43) | LMNAHPGD | |
| SCHEMBL19539238 | 0.79 | — | — | |
| SCHEMBL19566786 | 0.75 | LMNA (0.49) | LMNAHPGD | |
| SCHEMBL13411548 | 0.75 | LMNA (0.49) | LMNAHPGD | |
| SCHEMBL1634885 | 0.73 | LMNA (0.44) | LMNAHPGD | |
| SCHEMBL1635905 | 0.73 | LMNA (0.44) | LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230323345-A1 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | ARCTURUS THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| WO-2021257916-A1 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | ARCTURUS THERAPEUTICS, INC. (US) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021257917-A1 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | ARCTURUS THERAPEUTICS, INC. (US) | 2021-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230323345-A1 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | UPF1, HNRNPUL1, HNRNPUL2 | LMNA 657/4885HPGD 4641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.